Waltham, MA-based BG Medicine (NASDAQ: [[ticker:BGMD]]) started trading publicly today at $7 per share. After indicating earlier in the week that it had planned to offer 4.75 million shares in its initial public offering, the diagnostics company sold 5 million shares. Lazard Capital Markets acted as sole book-running manager for the deal, and underwriters will have the 30-day option to purchase an additonal 750,000 shares of common stock to cover over-allotments. BG shares had risen by more than 12 percent as of 2:19 pm EST, to hit $7.89 apiece.
Author: Erin Kutz
Erin Kutz has a background in covering business, politics and general news. She holds a bachelor’s degree in journalism from Boston University. Erin previously worked in the Boston bureau of Reuters, where she wrote articles on the investment management and mutual fund industries. While in college, she researched for USA Today reporter Jayne O’Donnell’s book, Gen Buy: How Tweens, Teens and Twenty-Somethings Are Revolutionizing Retail. She also spent a semester in Washington, DC, reporting Capitol Hill stories as a correspondent for two Connecticut newspapers and interning in the Money section of USA Today, where she assisted with coverage on the retail and small business beats. Erin got her first taste of reporting at Boston University’s independent student newspaper, as a city section reporter and fact checker and editor of the paper’s weekly business section.
View all posts by Erin Kutz
